Quick access to main page (top) Direct access to main contents Quick access to main page (bottom)

CagriSema Fails to Meet Expectations in Late-Stage Obesity Trial, but Still Beats Placebo

Daniel Kim Views  

Medical Today

Novo Nordisk’s obesity treatment CagriSema showed research results that fell short of expectations.

The company announced Monday that its new obesity treatment, CagriSema, did not meet expectations in late-stage clinical trials.

Cagrisema has garnered attention as a next-generation obesity treatment. It is expected to surpass Novo Nordisk’s Wegovy and competitor Eli Lilly’s Mounjaro.

The recently conducted REDEFINE 2 clinical trial involved 1,200 adults with a body mass index (BMI) of 27 or higher and type 2 diabetes.

The weight loss rate was 13.7% when including patients who dropped out by week 68 and 15.7% when excluding those who dropped out. This was significantly higher than the 3.1% weight loss rate observed in the placebo group.

Novo Nordisk reported that while the weight loss effect of CagriSema is superior to that of Wegovy, it is lower than expected compared to what was anticipated to be dramatic.

Meanwhile, CagriSema is manufactured by adding Cagrilintide, a component similar to the pancreatic hormone Amylin, to Semaglutide, the active ingredient in Wegovy. The two components work together to suppress hunger and regulate blood sugar levels.

Daniel Kim
content@viewusglobal.com

Comments0

300

Comments0

[LIFESTYLE] Latest Stories

  • Pilates: The Low-Impact Workout with Big Benefits for Your Body and Mind
  • Are Your Favorite Foods Actually Aging You? The Truth About Glycotoxins
  • Best Workouts for Your Knees: Keeping Arthritis at Bay
  • Are Probiotics Overrated? Experts Urge Caution Over Gut Health Claims
  • 5 Unexpected Benefits of Chewing Gum
  • Sugar-Free Doesn't Always Mean Safe: Health Risks of Zero-Calorie Sodas

You May Also Like

  • 1
    ID.EVERY1: Volkswagen's $21K Electric Vehicle Aims to Make Green Driving Accessible

    BUSINESS 

  • 2
    Toyota’s bZ3X SUV Surges with 10,000 Pre-Orders: A New Era in EVs

    BUSINESS 

  • 3
    Telo Trucks' MT1: A 500-HP Compact Pickup That Packs Big Punch in a Small Frame

    BUSINESS 

  • 4
    Xiaomi’s Success vs. Apple’s Failure: What’s the Difference?

    DEBATE 

  • 5
    Mitsubishi Delica D:2 Facelift: New Design, Better Fuel Economy, and Enhanced Safety

    BUSINESS 

Popular Now

  • 1
    Major Vehicle Recall: Over 15,000 Cars Affected Across Multiple Brands in South Korea

    BUSINESS&nbsp

  • 2
    Blazer EV SS Hits New Highs: 615 Horsepower and 3.4-Second 0-60 Acceleration

    BUSINESS&nbsp

  • 3
    Trump Defends Tesla, Promises Action Against Violent Attacks

    DEBATE&nbsp

  • 4
    Land Rover’s New Defender 130: Luxury Meets Off-Road Performance in a Seven-Seater

    BUSINESS&nbsp

  • 5
    Honda's New NSX Successor: 1,000 HP Electric Supercar Expected by 2027

    BUSINESS&nbsp

Must-Reads

  • 1
    ID.EVERY1: Volkswagen's $21K Electric Vehicle Aims to Make Green Driving Accessible

    BUSINESS 

  • 2
    Toyota’s bZ3X SUV Surges with 10,000 Pre-Orders: A New Era in EVs

    BUSINESS 

  • 3
    Telo Trucks' MT1: A 500-HP Compact Pickup That Packs Big Punch in a Small Frame

    BUSINESS 

  • 4
    Xiaomi’s Success vs. Apple’s Failure: What’s the Difference?

    DEBATE 

  • 5
    Mitsubishi Delica D:2 Facelift: New Design, Better Fuel Economy, and Enhanced Safety

    BUSINESS 

Popular Now

  • 1
    Major Vehicle Recall: Over 15,000 Cars Affected Across Multiple Brands in South Korea

    BUSINESS 

  • 2
    Blazer EV SS Hits New Highs: 615 Horsepower and 3.4-Second 0-60 Acceleration

    BUSINESS 

  • 3
    Trump Defends Tesla, Promises Action Against Violent Attacks

    DEBATE 

  • 4
    Land Rover’s New Defender 130: Luxury Meets Off-Road Performance in a Seven-Seater

    BUSINESS 

  • 5
    Honda's New NSX Successor: 1,000 HP Electric Supercar Expected by 2027

    BUSINESS